Search research articles
Contact Us
Filters
Showing results (291-300 of 302) with videos related to
Page
of 31
Sort By:
JAMA Oncology
|
August 14, 2020
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial
Ke-Da Yu, Fu-Gui Ye, Min He, et al.
BMJ (Clinical Research Ed.)
|
October 23, 2024
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
Min He, Yi-Zhou Jiang, Yue Gong, et al.
Signal Transduction and Targeted Therapy
|
June 18, 2026
Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer
Xiang-Rong Wu, Hong Lv, Shen Zhao, et al.
Nature Communications
|
September 30, 2025
Forward and reverse genomic screens enhance the understanding of phenotypic variation in a large Chinese rhesus macaque cohort
Bao-Lin Zhang, Yongxuan Chen, Yali Zhang, et al.
Molecular Cancer
|
December 20, 2025
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)
Xi-Yu Liu, Xin-Yi Sui, Ying Xu, et al.
Breast Cancer Research and Treatment
|
September 14, 2007
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified
Wen-Feng Li, Zhen Hu, Nan-Yan Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Li Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.
Nature Communications
|
November 11, 2020
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing
Guan-Tian Lang, Yi-Zhou Jiang, Jin-Xiu Shi, et al.
The Lancet. Oncology
|
January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
Research (Washington, D.C.)
|
August 1, 2025
A Study of Spontaneous Self-Injurious Behavior and Neuroimaging in Rhesus Macaques
Ya-Li Zhang, Yi-Cheng Qiao, Yun-Chao Ji, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 302) with videos related to
Sort By:
Page
of 31
JAMA Oncology
|
August 14, 2020
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial
Ke-Da Yu, Fu-Gui Ye, Min He, et al.
BMJ (Clinical Research Ed.)
|
October 23, 2024
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
Min He, Yi-Zhou Jiang, Yue Gong, et al.
Signal Transduction and Targeted Therapy
|
June 18, 2026
Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer
Xiang-Rong Wu, Hong Lv, Shen Zhao, et al.
Nature Communications
|
September 30, 2025
Forward and reverse genomic screens enhance the understanding of phenotypic variation in a large Chinese rhesus macaque cohort
Bao-Lin Zhang, Yongxuan Chen, Yali Zhang, et al.
Molecular Cancer
|
December 20, 2025
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)
Xi-Yu Liu, Xin-Yi Sui, Ying Xu, et al.
Breast Cancer Research and Treatment
|
September 14, 2007
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified
Wen-Feng Li, Zhen Hu, Nan-Yan Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Li Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.
Nature Communications
|
November 11, 2020
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing
Guan-Tian Lang, Yi-Zhou Jiang, Jin-Xiu Shi, et al.
The Lancet. Oncology
|
January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
Research (Washington, D.C.)
|
August 1, 2025
A Study of Spontaneous Self-Injurious Behavior and Neuroimaging in Rhesus Macaques
Ya-Li Zhang, Yi-Cheng Qiao, Yun-Chao Ji, et al.
Page
of 31